Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BL22 and lymphoid malignancies.

Robert J Kreitman1, Ira Pastan

  • 1Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892-4255, USA. kreitmar@mail.nih.gov

Best Practice & Research. Clinical Haematology
|September 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

USP40 protects podocytes by deubiquitylating integrin β1.

Biochemical and biophysical research communications·2026
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

Science translational medicine·2026
Same author

Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies.

Antibody therapeutics·2026
Same author

RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy.

Antibody therapeutics·2026

BL22, an anti-CD22 immunotoxin, shows significant activity in chemoresistant hairy-cell leukemia, inducing complete remission in 61% of patients. Further trials are underway to mitigate dose-limiting hemolytic uremic syndrome.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Hairy-cell leukemia (HCL) is often chemoresistant.
  • BL22 is a novel recombinant immunotoxin targeting the CD22 antigen.

Purpose of the Study:

  • To evaluate the safety and efficacy of BL22 in patients with chemoresistant HCL.
  • To investigate the mechanism of action and dose-limiting toxicities of BL22.

Main Methods:

  • Phase I clinical trial of BL22 in patients with HCL.
  • BL22 mechanism involves CD22 binding, endocytosis, cytoplasmic translocation, and elongation factor 2 inactivation.

Main Results:

  • BL22 demonstrated high activity in chemoresistant HCL, with 61% of 31 patients achieving complete remission.

Related Experiment Videos

  • Cytopenias improved in responders.
  • Reversible hemolytic uremic syndrome (HUS) was the dose-limiting toxicity, observed in cycles 2-3.

    • Conclusions:

    • BL22 is an active agent in chemoresistant HCL.
    • Modified protocols are being investigated in ongoing Phase II HCL and Phase I chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) trials to prevent HUS.